ALSO NOTED: Genzyme has made best offer for Bioenvision; Pfizer wants investigators to pursue ex-employee; GSK licenses IP; and

> Genzyme says its current bid for all the shares of Bioenvision it doesn't already own is its best and final offer. Release

> Pfizer wants the feds to throw the book at a former employee who copied personal data on some 34,000 workers and took it off site. Report

> GlaxoSmithKline has licensed reverse genetics IP for influenza vaccine strains from MedImmune. Release

> Medarex and PharmAthene have received a $14 million contract from the U.S. government to continue funding an anthrax vaccine. Release

> San Diego-based Asphelia Pharmaceuticals has named Francois-Xavier Frapaise, M.D.,as president and CEO. Release

> The FDA issued a warning yesterday on Fentora, the Cephalon painkiller recently linked to three deaths. Report

> As Novartis CEO Daniel Vasella predicted last week, the FDA has rejected the company's Cox-2 painkiller Prexige. Report

And Finally... Researchers at MIT have developed a computer model which they say can rev up the effectiveness of an antibody-based therapy. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.